Outstanding Inventors from France, Germany, Ireland, Netherlands, Switzerland and the US Honoured with European Inventor Award 2018
The EPO announced the winners of the European Inventor Award 2018 at a ceremony today in Paris, Saint-Germain-en-Laye, attended by some 600 guests from the areas of politics, business, intellectual property, science and academia.
Overall, the most elite ranks of Europe’s Most Innovative Universities have held steady from last year. The list was compiled in partnership with Clarivate Analytics, and is based on proprietary data and analysis of patent filings and research paper citations.
Economists show increased research efforts are yielding decreasing returns. Too much innovation veneration! One driver of the replication crisis is our culture’s growing obsession with “innovation.” As technology historians Lee Vinsel and Andrew Russell state in their influential Aeon essay Hail the Maintainers: “Entire societies have come to talk about innovation as if it were an inherently desirable value."
Like Darpa, Jedi will aim to deliver developmental milestones along the path to strategically important technologies, including through prototyping. It will sit between academia and industry and fund projects lasting no more than two years.
Edge Factors: Scientific Frontier Positions of Nations
The United States and South Korea have the highest tendencies for novel science. China has become a leader in favoring newer ideas when working with basic science ideas and research tools, but is still slow to adopt new clinical ideas. Many locations remain far behind the leaders in terms of their tendency to work with novel ideas.
Alphabet, the parent company of Google, is launching a new company under the Alphabet umbrella. It's called Chronicle, and the new company wants to apply the usual Google tenets of machine learning and cloud computing to cybersecurity.
Efforts to engage life science companies in open innovation have been hampered by the industry’s continued reticence to share. The result is shrinking pipelines, a wave of drug patent expirations ending in sudden drops in revenue, and poorly served public health.